疾病进展轨迹曲线用于估计阿尔茨海默病试验中节省的时间
Guogen Shan1, Yahui Zhang1, Zhixin Tang1
1Department of Biostatistics, University of Florida, Gainesville, FL 32610, United States of America.
Contemporary clinical trials
|February 9, 2025
概括
测量阿尔茨海默病 (AD) 治疗效果的新方法,如"节省时间",提供了更清晰的见解. 拟议的斜率调整和曲线下面积方法在AD临床试验中提供了更准确的治疗疗效解释.
科学领域:
- 神经学 神经学
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 阿尔茨海默病 (AD) 治疗的最新进展需要对治疗效果进行易于解释的测量.
- 目前的方法,如减少结果下降的百分比,比"节省时间"对患者的益处更不直观.
- 现有的"节省时间"计算依赖于安慰剂进展和最后一次诊所治疗效应.
研究的目的:
- 在AD临床试验中开发和评估计算"节省时间"的新方法.
- 用现实世界的试验数据和模拟来比较拟议的方法与现有的方法.
主要方法:
- 提出了两种新方法:斜率调整方法和曲线下面积 (AUC) 方法,利用治疗和安慰剂组的疾病进展轨迹.
- 将这些方法应用于阿尔茨海默病的donanemab和donepezil试验的数据.
- 进行模拟研究,以比较新方法与现有方法的性能.
主要成果:
- 曲线方法下的面积通常会产生更长的"节省时间",当治疗效应恒定或显示早期/中期疾病进展差异时.
- 调整斜率的方法可能会显示更大的"节省时间"疾病修饰疗法与时间依赖的治疗效果.
- 曲线方法下的面积经常显示最小的标准偏差,表明更高的精度.
结论:
- 拟议的斜率调整和曲线下面积方法为测量阿尔茨海默病治疗效果提供了更好的解释性和潜在的更高的灵敏度.
- 与现有方法相比,这些新的方法可以提供更全面的治疗疗效洞察力,特别是对于疾病修饰疗法.
- 曲线方法下的面积在估计"节省时间"时的准确性方面表现出有希望.
相关概念视频
Alzheimer's Disease: Overview
432
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
432
Alzheimer's Disease: Treatment
155
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
155


